par Degroote, Helena;Callebout, Eduard;Iesari, Samuele;Dekervel, Jeroen;Schreiber, Jonas 
;Pirenne, Jacques;Verslype, Chris;Ysebaert, Dirk;Michielsen, Peter;Lucidi, Valerio ;Moreno, Christophe ;Detry, Olivier;Delwaide, Jean;Troisi, Roberto Ivan Van R.I.;Lerut, Jan Paul;Van Vlierberghe, Hans
Référence Surgical oncology, 33, page (231-238)
Publication Publié, 2020-06-01
;Pirenne, Jacques;Verslype, Chris;Ysebaert, Dirk;Michielsen, Peter;Lucidi, Valerio ;Moreno, Christophe ;Detry, Olivier;Delwaide, Jean;Troisi, Roberto Ivan Van R.I.;Lerut, Jan Paul;Van Vlierberghe, HansRéférence Surgical oncology, 33, page (231-238)
Publication Publié, 2020-06-01
Article révisé par les pairs
| Résumé : | BACKGROUND: Recent studies indicate that a group of patients with cirrhosis receiving a liver transplantation for hepatocellular cancer (HCC) beyond the Milan Criteria (MC) can achieve a similar outcome compared to patients within these criteria. This study aims to investigate the value of the Asan critera (AC), up-to-7 criteria (UT7), French alpha-foetoprotein (AFP) model and Metroticket 2.0 (MT2.0) model compared to the MC. METHODS: 526 patients transplanted for non-metastatic HCC were analyzed. Patient groups within and beyond MC and extended criteria were determined according to radiological assessment and AFP value at listing. RESULTS: Overall survival (OS) and recurrence (RR) rates were similar between patients within MC and all extended criteria. Five-year OS within MC was 71.3% compared to 70.9% for AC, 71.4% for UT7, 69.7% for AFP-model and 71.0% for MT2.0 criteria. Five-year RR within MC was 12.3% compared to 13.5% for AC, 13.0% for UT7, 14.3% for AFP-model and 13.2% for MT2.0 criteria. Patients beyond MC but within the extended criteria had tendency towards higher recurrence. CONCLUSIONS: All validated extended criteria (AC, UT7, AFP-model and MT2.0) could be proposed as alternatives to the MC with similar outcome. Prospective data are awaited to assess recurrence beyond MC. |
